Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meloxicam/rizatriptan - Axsome Therapeutics

Next Previous
Drug Profile

Meloxicam/rizatriptan - Axsome Therapeutics

Alternative Names: AXS 07; MoSEIC™ meloxicam and rizatriptan; MoSEIC™ meloxicam/rizatriptan; SYMBRAVO

Latest Information Update: 13 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Axsome Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Analgesics; Antimigraines; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles; Tryptamines
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 05 May 2025 Axsome Therapeutics announces intention to launch for Migraine in the US, in June 2025
  • 24 Feb 2025 Efficacy and adverse event data from phase III EMERGE trial in Migraine released by Axsome Therapeutics
  • 04 Feb 2025 Planned Prescription Drug User Fee Act (PDUFA) date for Migraine in USA (PO) is 2022-04-30

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top